gonorrhea%20-%20uncomplicated%20anogenital%20infection
GONORRHEA - UNCOMPLICATED ANOGENITAL INFECTION
Gonorrhea is a sexually or vertically transmitted infection secondary to gram-negative diplococcus Neisseria gonorrhoeae.
It is one of the most common bacterial sexually transmitted infections that may cause pelvic inflammatory disease leading to infertility or ectopic pregnancy.
Most of the infected females are asymptomatic but may present with increased or altered vaginal discharge, dysuria, urethral discharge, abnormal vaginal bleeding, vulval itching or burning, dyspareunia, conjunctivitis and proctitis.

Introduction

  •  It is one of the most common sexually transmitted bacterial infections that may cause pelvic inflammatory disease (PID) leading to infertility or ectopic pregnancy

Definition

  • Gonorrhea is a sexually or vertically transmitted infection secondary to gram-negative diplococcus Neisseria gonorrhoeae

Signs and Symptoms

  • Most of the infected females are asymptomatic, but may present with:
    • Increased or altered vaginal discharge - most common
    • Dysuria
    • Urethral discharge
    • Abnormal vaginal bleeding
    • Vulval itching or burning
    • Dyspareunia
    • Conjunctivitis
    • Proctitis

Risk Factors

  • <25 years old
  • Unmarried
  • History of previous or concurrent sexually transmitted infection (STI)
  • New or >1 sex partner in the last 3 months
  • Sex partner currently has an STI
  • Sex partner with concurrent partners 
  • Inconsistent use of condom
  • Street involvement (youth on the streets, sex workers)
  • Injection drug use
  • Commercial sex worker
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Infectious Diseases - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
01 Sep 2018
High body mass index (BMI) appears to increase the risk of and worsen the outcomes for seasonal influenza, a recent study has found.
31 Aug 2018
New drug applications approved by US FDA as of 16 - 31 August 2018 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.